Status:
RECRUITING
Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock
Lead Sponsor:
STAVROS G DRAKOS
Conditions:
Cardiogenic Shock
Acute Myocardial Infarction
Eligibility:
All Genders
18+ years
Brief Summary
This large real-world international prospective registry will provide a unique opportunity to comprehensively understand the contemporary management, clinical course and short as well as long-term out...
Detailed Description
Cardiogenic shock (CS) is a hemodynamically complex and morbid syndrome characterized by frank circulatory collapse and end organ malperfusion stemming from severely impaired myocardial contractility....
Eligibility Criteria
Inclusion
- Primary diagnosis of cardiogenic shock at time of index evaluation; including acute myocardial infarction- and acute decompensated heart failure-cardiogenic shock phenotypes
- Patients with cardiac arrest complicating cardiogenic shock and those with massive pulmonary embolism with right ventricular cardiogenic shock will also be eligible for the registry
Exclusion
- Patients with shock not due to primary cardiac etiology will be excluded. These include septic, hemorrhagic, and anaphylactic shock.
Key Trial Info
Start Date :
May 25 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05185492
Start Date
May 25 2022
End Date
December 31 2027
Last Update
February 7 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic Florida
Weston, Florida, United States, 33331
2
Inova Heart and Vascular Institute
Falls Church, Virginia, United States, 22042
3
University of Toronto
Toronto, Ontario, Canada